The Minimal Residual Disease (MRD) Testing Market is a pivotal component of modern oncology diagnostics, playing a crucial role in assessing and monitoring the effectiveness of cancer treatments. This market is driven by the increasing incidence of cancer, advancements in genomic technologies, and the imperative need for personalized and targeted therapies. Major drivers include the growing...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian